LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

LLY

1,077

-2.36%↓

JNJ

223.52

-0.74%↓

ABBV

212.36

-2.57%↓

UNH

379.41

+0.2%↑

MRK

114.99

-3.04%↓

Strona główna・Stock List・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Closed

SectorHealthcare

17.12 -2.95

Buy Sell

Overview

Share price change

24h

Current

Min

16.99

Max

17.64

Key metrics
By Trading Economics
Income	-607K -51M
Sales	-28M 100M
EPS	-0.46
Profit margin	-51.215
Employees	1,784
EBITDA	4.1M -44M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+83.15% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	-308M 2.1B
Previous open	20.07
Previous close	17.12

News Sentiment

By Acuity

34%

66%

79 / 344 Ranking in Healthcare

Zai Lab Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 cze 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 cze 2026, 23:38 UTC

Acquisitions, Mergers, Takeovers

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 cze 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 cze 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 cze 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 cze 2026, 22:08 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 cze 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 cze 2026, 22:01 UTC

Acquisitions, Mergers, Takeovers

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 cze 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 cze 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 cze 2026, 21:22 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 cze 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 cze 2026, 20:46 UTC

Acquisitions, Mergers, Takeovers

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 cze 2026, 20:22 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 cze 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares $11 Special Div

1 cze 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 cze 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 cze 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 cze 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 cze 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 cze 2026, 18:54 UTC

Acquisitions, Mergers, Takeovers

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 cze 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 cze 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 cze 2026, 18:00 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 cze 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 cze 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 cze 2026, 17:10 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer Comparison

Price change

Zai Lab Ltd ADR Forecast

Price Target

By TipRanks

83.15% upside

12 Months Forecast

Average 32.4 USD 83.15%

High 44 USD

Low 21.6 USD

Based on 4 Wall Street analysts offering 12 month price targets forZai Lab Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Zai Lab Ltd ADR - Dist in the past 3 months.

Sentiment

By Acuity

79 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.